Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone

Abstract Background Sublingual tablet buprenorphine (BUP-SL) and oral liquid methadone (MET) are the daily, standard-of-care (SOC) opioid agonist treatment medications for opioid use disorder (OUD). A sizable proportion of the OUD treatment population is not exposed to sufficient treatment to attain...

Full description

Bibliographic Details
Main Authors: John Marsden, Mike Kelleher, Zoë Hoare, Dyfrig Hughes, Jatinder Bisla, Angela Cape, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Andrea Hearn, Joanna Kelly, Natalie Lowry, Martin McCusker, Caroline Murphy, Robert Murray, Tracey Myton, Sophie Quarshie, Gemma Scott, Sophie Turner, Rob Vanderwaal, April Wareham, Eilish Gilvarry, Luke Mitcheson
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Opioid use disorder
Long-acting injectable buprenorphine
Extended-release buprenorphine
Psychosocial intervention
Randomised controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06595-0

Internet

https://doi.org/10.1186/s13063-022-06595-0

Similar Items